AUG 3·SEC EDGARLow
de Boer Daniel Anton purchased $354K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 200,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.77 ($0.35M total) on 2026-07-31.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PRQR
ProQR Therapeutics N.V.
Price · $PRQRvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $PRQR in the last 7 days.
Insider · 30dAll trades →
- Buys
- $612K 2 txs
- Sells
- — 0 txs
de Boer Daniel Anton1× · $354K
10b5-1 plan0%
Top stories · $PRQRMore →
JUL 21·SEC EDGAR
Filius Bart purchased $258K of PRQR
Filius Bart purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.72 ($0.26M total) on 2026-07-17.
JUL 13·SEC EDGAR
de Boer Daniel Anton purchased $261K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.74 ($0.26M total) on 2026-07-09.
PRQR sentiment & insider activity
Recent PRQR coverage spans insider activity and financial news.
In the last 30 days, PRQR insiders filed 2 SEC Form 4 transactions — 2 purchases ($612K) and no sales. The most active reporter was de Boer Daniel Anton, Chief Executive Officer, with 1 filing.
What's driving PRQR
The filing is a fresh insider buy, which can modestly support sentiment but is not a fundamental catalyst by itself.
The filing is a fresh insider open-market purchase that may modestly support sentiment, but it is not a fundamental catalyst.
Insider buying can be a modest sentiment signal, but this specific Form 4 is unlikely to drive a large, immediate repricing by itself.
This is a disclosed insider open-market purchase by the CEO, which can modestly support sentiment but is not a fundamental catalyst.
The filing is a disclosed insider open-market purchase by a director, which can modestly support sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions PRQR with an AI model for sentiment and relevance, and aggregates insider trades from ProQR Therapeutics N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PRQR
Score
de Boer Daniel Anton purchased $354K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 200,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.77 ($0.35M total) on 2026-07-31.
1 min readFilius Bart purchased $258K of PRQR
Filius Bart purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.72 ($0.26M total) on 2026-07-17.
2 min readde Boer Daniel Anton purchased $261K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.74 ($0.26M total) on 2026-07-09.
1 min readde Boer Daniel Anton purchased $238K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.59 ($0.24M total) on 2026-07-07.
1 min readFilius Bart purchased $231K of PRQR
Filius Bart purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.54 ($0.23M total) on 2026-06-26.
2 min read
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
ProQR Therapeutics N.V. (Nasdaq: PRQR) has nominated Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Gylvin brings over 20 years of global leadership experience in drug development across various therapeutic areas. Her nomination will be submitted for shareholder approval at the company's upcoming Annual General Meeting.
2 min read
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase
ProQR Therapeutics has nominated Dr. Lykke Hinsch Gylvin, CMO of Boehringer Ingelheim, to its board of directors as an independent non-executive member, pending shareholder approval. This move aims to strengthen ProQR’s board with extensive global drug-development expertise, crucial as the company advances its Axiomer RNA editing pipeline. Dr. Hinsch Gylvin's experience is expected to bolster ProQR's long-term growth strategy and enhance investor confidence.
2 min readWhy Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge
ProQR Therapeutics N.V. (NASDAQ:PRQR) has experienced a 28% share price drop in the last month, contributing to a 26% decline over the past year. The company's low price-to-sales (P/S) ratio of 9.4x, compared to an industry average of 12.4x, reflects investor concerns about its declining revenue, which fell by 13% last year. While analysts forecast 54% annual revenue growth for the next three years, this is significantly lower than the broader industry's 123% forecast, explaining the depressed P/S ratio and investor pessimism.
4 min readProQR Announces Third Quarter 2025 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- ProQR Therapeutics N.V. ( Nasdaq: PRQR ) ( ProQR ) , a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its ...
3 min readProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- ProQR Therapeutics N.V. ( Nasdaq: PRQR ) ( ProQR ) , a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that ...
2 min read